Fundraising Fox
Gondolabio
Founded 2024 · 102 employees on LinkedIn · 4 known investors
Find your way into Gondolabio
Sign up to see every warm intro you have to Gondolabio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Gondolabio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
GondolaBio is a clinical-stage biopharmaceutical company developing therapeutics for patients with genetic diseases, with a lead oral small-molecule program (PORT-77) targeting erythropoietic protoporphyria and X-linked protoporphyria. A sister company of BridgeBio Pharma launched in 2024, it runs a decentralized drug-development model with a pipeline spanning multiple rare genetic conditions.
Investors · 4
Frequently asked questions
- What does Gondolabio do?
- GondolaBio is a clinical-stage biopharmaceutical company developing therapeutics for patients with genetic diseases, with a lead oral small-molecule program (PORT-77) targeting erythropoietic protoporphyria and X-linked protoporphyria. A sister company of BridgeBio Pharma launched in 2024, it runs a decentralized drug-development model with a pipeline spanning multiple rare genetic conditions.
- Who are Gondolabio's investors?
- Gondolabio's investors include Aisling Capital, Frazier Life Sciences, Patient Square Capital, Viking Global.